{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:27:21Z","timestamp":1788582441898,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R167-A11045-17-S2"],"award-info":[{"award-number":["R167-A11045-17-S2"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012526","name":"Sundhedsvidenskabelige Fakultet, Aarhus Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012526","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005940","name":"Dansk Kr\u00e6ftforsknings Fond","doi-asserted-by":"publisher","award":["PLESNER\u2013FAST\u2013Active.FID1839672"],"award-info":[{"award-number":["PLESNER\u2013FAST\u2013Active.FID1839672"]}],"id":[{"id":"10.13039\/501100005940","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R167\u20132013\u201315861"],"award-info":[{"award-number":["R167\u20132013\u201315861"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer institute","award":["R01CA166825"],"award-info":[{"award-number":["R01CA166825"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Breast cancer treatment is associated with adverse effects, which may delay return-to-work. Single nucleotide polymorphisms (SNPs) may influence the risk and severity of treatment toxicities, which in turn could delay return-to-work. We examined the association of 26 SNPs with return-to-work in premenopausal women with breast cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using Danish registries, we identified premenopausal women diagnosed with non-distant metastatic breast cancer during 2007\u20122011, assigned adjuvant combination chemotherapy including cyclophosphamide and docetaxel. We genotyped 26 SNPs in 20 genes (<jats:italic>ABCB1, ABCC2, ABCG2, CYP1A1, CYP1B1, CYP3A, CYP3A4, CYP3A5, GSTP1, SLCO1B1, SLCO1B3, ARHGEF10, EPHA4, EPHA5, EPHA6, EPHA8, ERCC1, ERCC2, FGD4 and TRPV1)<\/jats:italic> using TaqMan assays. We computed the cumulative incidence of return-to-work (defined as 4 consecutive weeks of work) up to 10\u00a0years after surgery, treating death and retirement as competing events and fitted cause-specific Cox regression models to estimate crude hazard ratios (HRs) and 95% confidence intervals (CIs) of return-to-work. We also examined stable labor market attachment (defined as 12 consecutive weeks of work).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 1,964 women. No associations were found for 25 SNPs. The cumulative incidence of return-to-work varied by <jats:italic>CYP3A5<\/jats:italic> rs776746 genotype. From 6\u00a0months to 10\u00a0years after surgery, return-to-work increased from 25 to 94% in wildtypes (<jats:italic>n<\/jats:italic>\u2009=\u20091600), from 17 to 94% in heterozygotes (<jats:italic>n<\/jats:italic>\u2009=\u2009249), and from 7 to 82% in homozygotes (<jats:italic>n<\/jats:italic>\u2009=\u200915). The HR showed delayed return-to-work in <jats:italic>CYP3A5<\/jats:italic> rs776746 homozygotes throughout follow-up (0.48, 95% CI 0.26, 0.86), compared with wildtypes. Estimates were similar for stable labor market attachment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Overall, the SNPs examined in the study did not influence return-to-work or stable labor market attachment after breast cancer in premenopausal women. Our findings did suggest that the outcomes were delayed in homozygote carriers of <jats:italic>CYP3A5<\/jats:italic> rs776746, though the number of homozygotes was low.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00280-022-04499-z","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T14:03:27Z","timestamp":1672841007000},"page":"157-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-8531","authenticated-orcid":false,"given":"Cathrine F.","family":"Hjorth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Damkier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore B.","family":"Stage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Feddersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hamilton-Dutoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bent","family":"Ejlertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy L.","family":"Lash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"B\u00f8ggild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik T.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"Cronin-Fenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"4499_CR1","unstructured":"International Agency for Research on Cancer (2020) Latest global cancer data: Cancer burden rises to 19.3 million new cases. Press release N\u00b0 292. World Health Organization"},{"key":"4499_CR2","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1002\/pon.3285","volume":"22","author":"MH Lundh","year":"2013","unstructured":"Lundh MH, Lampic C, Nordin K, Ahlgren J, Bergkvist L, Lambe M et al (2013) Changes in health-related quality of life by occupational status among women diagnosed with breast cancer\u2014a population-based cohort study. Psychooncology 22:2321\u20132331","journal-title":"Psychooncology"},{"key":"4499_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3233\/WOR-182810","volume":"61","author":"RA Cocchiara","year":"2018","unstructured":"Cocchiara RA, Sciarra I, D\u2019Egidio V, Sestili C, Mancino M, Backhaus I et al (2018) Returning to work after breast cancer: a systematic review of reviews. Work 61:463\u2013476","journal-title":"Work"},{"key":"4499_CR4","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/0284186X.2018.1557341","volume":"58","author":"V Arndt","year":"2019","unstructured":"Arndt V, Koch-Gallenkamp L, Bertram H, Eberle A, Holleczek B, Pritzkuleit R et al (2019) Return to work after cancer. A multi-regional population-based study from Germany. Acta Oncol Stockh Swed. 58:811\u2013818","journal-title":"Acta Oncol Stockh Swed."},{"key":"4499_CR5","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1186\/1471-2458-14-S3-S8","volume":"14","author":"T Islam","year":"2014","unstructured":"Islam T, Dahlui M, Majid HA, Nahar AM, Mohd Taib NA, Su TT (2014) Factors associated with return to work of breast cancer survivors: a systematic review. BMC Public Health 14:S8","journal-title":"BMC Public Health"},{"key":"4499_CR6","first-page":"783","volume":"55","author":"W Sun","year":"2016","unstructured":"Sun W, Chen K, Terhaar A, Wiegmann DA, Heidrich SM, Tevaarwerk AJ et al (2016) Work-related barriers, facilitators, and strategies of breast cancer survivors working during curative treatment. Work Read Mass 55:783\u2013795","journal-title":"Work Read Mass"},{"key":"4499_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10926-017-9736-8","volume":"28","author":"R Bijker","year":"2018","unstructured":"Bijker R, Duijts SFA, Smith SN, de Wildt-Liesveld R, Anema JR, Regeer BJ (2018) Functional impairments and work-related outcomes in breast cancer survivors: a systematic review. J Occup Rehabil 28:429\u2013451","journal-title":"J Occup Rehabil"},{"key":"4499_CR8","unstructured":"Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL et al (2018) Breast Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 9 Oct 2018"},{"key":"4499_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10926-013-9474-5","volume":"24","author":"AGEM de Boer","year":"2014","unstructured":"de Boer AGEM (2014) The European Cancer and Work Network: CANWON. J Occup Rehabil 24:393\u2013398","journal-title":"J Occup Rehabil"},{"key":"4499_CR10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/cncr.30421","volume":"123","author":"T Watanabe","year":"2017","unstructured":"Watanabe T, Kuranami M, Inoue K, Masuda N, Aogi K, Ohno S et al (2017) Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study. Cancer 123:759\u2013768","journal-title":"Cancer"},{"key":"4499_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3109\/0284186X.2014.995775","volume":"54","author":"M Ewertz","year":"2015","unstructured":"Ewertz M, Qvortrup C, Eckhoff L (2015) Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol Stockh Swed 54:587\u2013591","journal-title":"Acta Oncol Stockh Swed"},{"key":"4499_CR12","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1200\/JCO.2005.04.0543","volume":"24","author":"JJ Lee","year":"2006","unstructured":"Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24:1633\u20131642","journal-title":"J Clin Oncol"},{"key":"4499_CR13","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3109\/0284186X.2011.602111","volume":"50","author":"L Eckhoff","year":"2011","unstructured":"Eckhoff L, Nielsen M, Moeller S, Knoop A (2011) TAXTOX\u2014a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Acta Oncol Stockh Swed 50:1075\u20131082","journal-title":"Acta Oncol Stockh Swed"},{"key":"4499_CR14","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1158\/1078-0432.CCR-12-1590","volume":"18","author":"RM Baldwin","year":"2012","unstructured":"Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C et al (2012) A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 18:5099\u20135109","journal-title":"Clin Cancer Res"},{"key":"4499_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jns.2015.06.056","volume":"357","author":"GK Boora","year":"2015","unstructured":"Boora GK, Kulkarni AA, Kanwar R, Beyerlein P, Qin R, Banck MS et al (2015) Association of the Charcot\u2013Marie\u2013Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). J Neurol Sci 357:35\u201340","journal-title":"J Neurol Sci"},{"key":"4499_CR16","first-page":"530","volume":"54","author":"L Eckhoff","year":"2015","unstructured":"Eckhoff L, Feddersen S, Knoop AS, Ewertz M, Bergmann TK (2015) Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer. Acta Oncol Stockh Swed 54:530\u2013537","journal-title":"Acta Oncol Stockh Swed"},{"key":"4499_CR17","doi-asserted-by":"publisher","first-page":"5073","DOI":"10.2147\/OTT.S106574","volume":"9","author":"T Kus","year":"2016","unstructured":"Kus T, Aktas G, Kalender ME, Demiryurek AT, Ulasli M, Oztuzcu S et al (2016) Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. OncoTargets Ther 9:5073\u20135080","journal-title":"OncoTargets Ther"},{"key":"4499_CR18","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1158\/1055-9965.EPI-19-0833","volume":"29","author":"TP Ahern","year":"2020","unstructured":"Ahern TP, Collin LJ, Baurley JW, Kj\u00e6rsgaard A, Nash R, Maliniak ML et al (2020) Metabolic pathway analysis and effectiveness of tamoxifen in Danish breast cancer patients. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 29:582\u2013590","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"key":"4499_CR19","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S0140-6736(05)74803-0","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A (2005) ATAC trial update. Lancet 365:1225\u20131226","journal-title":"Lancet"},{"key":"4499_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2147\/CLEP.S179083","volume":"11","author":"M Schmidt","year":"2019","unstructured":"Schmidt M, Schmidt SAJ, Adelborg K, Sundb\u00f8ll J, Laugesen K, Ehrenstein V et al (2019) The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol 11:563\u2013591","journal-title":"Clin Epidemiol"},{"key":"4499_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","volume":"29","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Pedersen L, S\u00f8rensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29:541\u2013549","journal-title":"Eur J Epidemiol"},{"key":"4499_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/0284186X.2017.1404638","volume":"57","author":"M-B Jensen","year":"2018","unstructured":"Jensen M-B, Laenkholm A-V, Offersen BV, Christiansen P, Kroman N, Mouridsen HT et al (2018) The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007\u20132016. Acta Oncol 57:13\u201318","journal-title":"Acta Oncol"},{"key":"4499_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CLEP.S9908","volume":"2","author":"R Erichsen","year":"2010","unstructured":"Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L (2010) Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol 2:51\u201356","journal-title":"Clin Epidemiol"},{"issue":"7 Suppl","key":"4499_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/1403494811399958","volume":"39","author":"K Helweg-Larsen","year":"2011","unstructured":"Helweg-Larsen K (2011) The Danish Register of causes of death. Scand J Public Health 39(7 Suppl):26\u201329","journal-title":"Scand J Public Health"},{"key":"4499_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, S\u00f8rensen HT (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449\u2013490","journal-title":"Clin Epidemiol"},{"key":"4499_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10654-018-0356-1","volume":"33","author":"M Bliddal","year":"2018","unstructured":"Bliddal M, Broe A, Potteg\u00e5rd A, Olsen J, Langhoff-Roos J (2018) The Danish medical birth register. Eur J Epidemiol 33:27\u201336","journal-title":"Eur J Epidemiol"},{"issue":"7 Suppl","key":"4499_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/1403494810394715","volume":"39","author":"VM Jensen","year":"2011","unstructured":"Jensen VM, Rasmussen AW (2011) Danish education registers. Scand J Public Health 39(7 Suppl):91\u201394","journal-title":"Scand J Public Health"},{"issue":"7_suppl","key":"4499_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/1403494811405098","volume":"39","author":"M Baadsgaard","year":"2011","unstructured":"Baadsgaard M, Quitzau J (2011) Danish registers on personal income and transfer payments. Scand J Public Health 39(7_suppl):103\u2013105","journal-title":"Scand J Public Health"},{"key":"4499_CR29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/cesifo\/ifm015","volume":"53","author":"TM Andersen","year":"2007","unstructured":"Andersen TM, Svarer M (2007) Flexicurity\u2014labour market performance in Denmark*. CESifo Econ Stud 53:389\u2013429","journal-title":"CESifo Econ Stud"},{"key":"4499_CR30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/14034940701271882","volume":"35","author":"NH Hjollund","year":"2007","unstructured":"Hjollund NH, Larsen FB, Andersen JH (2007) Register-based follow-up of social benefits and other transfer payments: accuracy and degree of completeness in a Danish interdepartmental administrative database compared with a population-based survey. Scand J Public Health 35:497\u2013502","journal-title":"Scand J Public Health"},{"key":"4499_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021805","author":"LJ Collin","year":"2018","unstructured":"Collin LJ, Cronin-Fenton DP, Ahern TP, Christiansen PM, Damkier P, Ejlertsen B et al (2018) Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark. BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2018-021805","journal-title":"BMJ Open"},{"key":"4499_CR32","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1200\/JCO.2017.72.3494","volume":"35","author":"B Ejlertsen","year":"2017","unstructured":"Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen M-B, Knoop AS, H\u00f8jris I et al (2017) Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, phase III, randomized trial. J Clin Oncol 35:2639\u20132646","journal-title":"J Clin Oncol"},{"key":"4499_CR33","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alf\u00f6ldi J, Wang Q et al (2020) The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581:434\u2013443","journal-title":"Nature"},{"key":"4499_CR34","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1161\/CIRCULATIONAHA.116.021859","volume":"134","author":"R Rasmus","year":"2016","unstructured":"Rasmus R, Chih W, Kristian K, Fosb\u00f8l EL, Mogensen UM, Lamberts M et al (2016) Return to the workforce after first hospitalization for heart failure. Circulation 134:999\u20131009","journal-title":"Circulation"},{"key":"4499_CR35","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1161\/CIRCULATIONAHA.114.011366","volume":"131","author":"K Kristian","year":"2015","unstructured":"Kristian K, Mads W, Normark MR, Kirsten F, Eggert JS, Shahzleen R et al (2015) Return to work in out-of-hospital cardiac arrest survivors. Circulation 131:1682\u20131690","journal-title":"Circulation"},{"key":"4499_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcchd.2021.100160","volume":"4","author":"PD Evers","year":"2021","unstructured":"Evers PD, Farkas DK, Hjorth CF, Khoury M, Olsen M, Madsen NL (2021) Return to work following adverse cardiovascular events in adults with congenital heart disease. Int J Cardiol Congenit Heart Dis 4:100160","journal-title":"Int J Cardiol Congenit Heart Dis"},{"key":"4499_CR37","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s10926-012-9405-x","volume":"23","author":"K Biering","year":"2013","unstructured":"Biering K, Hj\u00f8llund NH, Lund T (2013) Methods in measuring return to work: a comparison of measures of return to work following treatment of coronary heart disease. J Occup Rehabil 23:400\u2013405","journal-title":"J Occup Rehabil"},{"key":"4499_CR38","unstructured":"Amin MB, American Joint Committee on Cancer, American Cancer Society, editors (2017) AJCC cancer staging manual. Eight edition \/ editor-in-chief, Mahul B. Amin, MD, FCAP ; editors, Stephen B. Edge, MD, FACS [and 16 others] ; Donna M. Gress, RHIT, CTR-Technical editor ; Laura R. Meyer, CAPM-Managing editor. American Joint Committee on Cancer, Springer, Chicago"},{"key":"4499_CR39","unstructured":"Rothman KJ, Lash T, Greenland S (2012) Modern Epidemiology. Third edition. Philadelphia Baltimore New York London Buenos Aires Hong Kong Sydney Tokyo: LWW"},{"key":"4499_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehb.2021.101057","volume":"43","author":"A Kollerup","year":"2021","unstructured":"Kollerup A, Ladenburg J, Heinesen E, Kolodziejczyk C (2021) The importance of workplace accommodation for cancer survivors\u2014the role of flexible work schedules and psychological help in returning to work. Econ Hum Biol 43:101057","journal-title":"Econ Hum Biol"},{"key":"4499_CR41","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/clpt.2008.95","volume":"85","author":"SD Baker","year":"2009","unstructured":"Baker SD, Verweij J, Cusatis GA, van Schaik R, Marsh S, Orwick SJ et al (2009) Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85:155\u2013163","journal-title":"Clin Pharmacol Ther"},{"key":"4499_CR42","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/tpj.2010.13","volume":"11","author":"S Leskel\u00e4","year":"2011","unstructured":"Leskel\u00e4 S, Jara C, Leandro-Garc\u00eda LJ, Mart\u00ednez A, Garc\u00eda-Donas J, Hernando S et al (2011) Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 11:121\u2013129","journal-title":"Pharmacogenomics J"},{"issue":"51","key":"4499_CR43","first-page":"292","volume":"2015","author":"L Eckhoff","year":"1990","unstructured":"Eckhoff L, Knoop A, Jensen MB, Ewertz M (1990) Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer Oxf Engl 2015(51):292\u2013300","journal-title":"Eur J Cancer Oxf Engl"},{"key":"4499_CR44","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00415-005-0887-8","volume":"252","author":"AA Argyriou","year":"2005","unstructured":"Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Kalofonos HP, Chroni E (2005) Paclitaxel plus carboplatin\u2013induced peripheral neuropathy: a prospective clinical and electrophysiological study in patients suffering from solid malignancies. J Neurol 252:1459\u20131464","journal-title":"J Neurol"},{"key":"4499_CR45","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1080\/0284186X.2017.1327720","volume":"56","author":"DP Cronin-Fenton","year":"2017","unstructured":"Cronin-Fenton DP, Kj\u00e6rsgaard A, Ahern TP, Mele M, Ewertz M, Hamilton-Dutoit S et al (2017) Validity of Danish Breast Cancer Group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort study. Acta Oncol 56:1155\u20131160","journal-title":"Acta Oncol"},{"key":"4499_CR46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/02841860310000737","volume":"42","author":"AR Jensen","year":"2003","unstructured":"Jensen AR, Storm HH, M\u00f8ller S, Overgaard J (2003) Validity and representativity in the Danish Breast Cancer Cooperative Group\u2014a study on protocol allocation and data validity from one county to a multi-centre database. Acta Oncol Stockh Swed 42:179\u2013185","journal-title":"Acta Oncol Stockh Swed"},{"key":"4499_CR47","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1186\/1471-2458-12-661","volume":"12","author":"CM Stapelfeldt","year":"2012","unstructured":"Stapelfeldt CM, Jensen C, Andersen NT, Fleten N, Nielsen CV (2012) Validation of sick leave measures: self-reported sick leave and sickness benefit data from a Danish national register compared to multiple workplace-registered sick leave spells in a Danish municipality. BMC Public Health 12:661","journal-title":"BMC Public Health"},{"key":"4499_CR48","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/sj.ejhg.5201410","volume":"13","author":"G Salanti","year":"2005","unstructured":"Salanti G, Amountza G, Ntzani EE, Ioannidis JPA (2005) Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet EJHG 13:840\u2013848","journal-title":"Eur J Hum Genet EJHG"},{"key":"4499_CR49","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/ije\/dym234","volume":"37","author":"C Minelli","year":"2008","unstructured":"Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J (2008) How should we use information about HWE in the meta-analyses of genetic association studies? Int J Epidemiol 37:136\u2013146","journal-title":"Int J Epidemiol"},{"issue":"15_suppl","key":"4499_CR50","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1200\/jco.2015.33.15_suppl.1528","volume":"33","author":"DL Hertz","year":"2015","unstructured":"Hertz DL, Kidwell KM, Thibert JN, Gersch CL, Regan MM, Skaar TC et al (2015) Comparison of genotyping performance in DNA extracted from matched FFPE tumor, FFPE lymph node, and whole blood for pharmacogenetic analyses. J Clin Oncol 33(15_suppl):1528\u20131528","journal-title":"J Clin Oncol"},{"key":"4499_CR51","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1016\/j.molonc.2015.07.002","volume":"9","author":"DL Hertz","year":"2015","unstructured":"Hertz DL, Kidwell KM, Thibert JN, Gersch C, Regan MM, Skaar TC et al (2015) Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. Mol Oncol 9:1868\u20131876","journal-title":"Mol Oncol"},{"key":"4499_CR52","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2147\/CLEP.S13811","volume":"2","author":"TP Ahern","year":"2010","unstructured":"Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, Rosenberg CL, S\u00f8rensen HT et al (2010) Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. Clin Epidemiol 2:241\u2013246","journal-title":"Clin Epidemiol"},{"key":"4499_CR53","unstructured":"Cyclophosphamide Pathway, Pharmacokinetics. PharmGKB. https:\/\/www.pharmgkb.org\/pathway\/PA2034. Accessed 12 Nov 2021"},{"key":"4499_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckx187.690","author":"L Jensen","year":"2017","unstructured":"Jensen L, Overgaard C, B\u00f8ggild H, Garne JP, Lund T, Overvad K et al (2017) The Long-term financial consequences of breast cancer: a Danish registry-based cohort study Laura Jensen. Eur J Public Health. https:\/\/doi.org\/10.1093\/eurpub\/ckx187.690","journal-title":"Eur J Public Health"},{"key":"4499_CR55","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1093\/aje\/kwaa130","volume":"189","author":"JW Baurley","year":"2020","unstructured":"Baurley JW, Kj\u00e6rsgaard A, Zwick ME, Cronin-Fenton DP, Collin LJ, Damkier P et al (2020) Bayesian pathway analysis for complex interactions. Am J Epidemiol 189:1610\u20131622","journal-title":"Am J Epidemiol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04499-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04499-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04499-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T08:10:30Z","timestamp":1676016630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04499-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["4499"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04499-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"18 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no support in relation to the present study. TBS receives consultancy fees from Pfizer and teaching fees from Orifarm, Eisai, Novartis, and Astellas Pharma. TLL receives consulting fees and travel support for his participation in the Amgen Methods Advisory Council. BE receives institutional grants from AstraZeneca, Eli Lilly, Merck Sharpe & Dohme, Novartis, Pfizer, Roche, and Samsung Bioepis. The Department of Clinical Epidemiology, Aarhus University Hospital, receives funding for other studies from European Medicines Agency and from companies in the form of research grants to (and administered by) Aarhus University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Danish Data Protection Agency (AU 2016-051-000001, #808), the Regional Ethics Committee (Record no. 1-10-72-4-18) and the Danish Breast Cancer Group (DBCG) (DBCG-2018-01-04) approved the study. The use of registry-based data for scientific studies in Denmark requires no consent from the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}